Business Context and Reporting Period
This Form 6-K filing by GSK plc covers the month of July 2022, with a specific reporting date of July 8, 2022. The document serves as a transaction notification regarding the acquisition of ordinary shares by Persons Discharging Managerial Responsibilities (PDMRs) and Persons Closely Associated (PCAs) with them.
Key Financial Metrics
The filing does not contain consolidated financial statements, revenue, profit, cash flow, margin, debt, or liquidity metrics for the company. It exclusively details specific share transactions executed on July 6, 2022, on the London Stock Exchange (XLON).
| Transaction Type | Instrument | Price per Share | Total Volume |
|---|---|---|---|
| Acquisition (Dividend Re-investment) | Ordinary Shares (25p each) | £17.9094 | 14,631.708 shares |
Note: The total volume represents the aggregate of all individual transactions listed in the filing.
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document records routine compliance disclosures for share acquisitions resulting from the re-investment of dividends paid to shareholders on July 1, 2022.
Guidance, Outlook, and Risks
The filing text does not provide management commentary, future guidance, outlook, risk factors, or contingencies. It is a statutory disclosure of insider trading activity.
Key Facts for Investor Verification
- Transaction Nature: All reported transactions were acquisitions of ordinary shares via dividend re-investment plans, not open market purchases or sales.
- Participants: Transactions involved 11 individuals, including the CEO (Ms E Walmsley), President of Vaccines and Global Health (Mr R Connor), and CEO of ViiV Healthcare (Ms D Waterhouse).
- Execution Details: All transactions occurred on July 6, 2022, at a uniform price of £17.9094 per share.
- Scope: This filing does not reflect the company's overall financial performance for the period; investors should refer to Form 20-F or quarterly reports for financial metrics.